Understanding why some people age faster than others — and what interventions actually slow biological deterioration — has been hampered by the absence of validated molecular markers that work across species and tissues. A landmark integrative study published in Nature now offers the most comprehensive transcriptomic map of mammalian aging to date, with direct implications for how clinicians might one day predict mortality risk and evaluate anti-aging therapies.
Drawing on more than 11,000 transcriptomes spanning 25 tissue types across mice, rats, macaques, and humans, researchers constructed multi-species biomarkers capable of estimating chronological age, predicting time to death, detecting chronic disease burden, and identifying rejuvenating interventions. The analysis converged on a conserved set of aging signals shared across cell types and species, prominently featuring CDKN1A (p21, a cell cycle arrest protein) and LGALS3 (galectin-3, linked to fibrosis and inflammation), whose circulating protein levels independently associated with mortality and multimorbidity in the UK Biobank. A modular network architecture was identified encompassing inflammation, interferon signaling, mitochondrial function, chromatin remodeling, and extracellular matrix organization — each contributing distinctly to the aging signal. Module-specific clocks revealed that chronic diseases primarily accelerate the inflammatory module, while interventions such as heterochronic parabiosis and cellular reprogramming selectively attenuate specific pathways.
This work is arguably paradigm-shifting for longevity science. Prior aging clocks — including epigenetic and proteomic clocks — have largely been human-centric or tissue-restricted, limiting their utility for preclinical translation. By anchoring findings in cross-species conservation and validating key proteins in a large population cohort, this study elevates CDKN1A and LGALS3 as candidate biomarkers worth pursuing in clinical aging trials. A key limitation is that transcriptomic snapshots cannot fully capture dynamic or post-translational regulation, and causal directionality between these signatures and mortality remains to be established. Still, the modular framework offers a principled way to evaluate which component of aging a given intervention actually targets — a critical gap the field has long needed to fill.
